Healthcare

HeraMED Limited (ASX:HMD)

Industry Group : Health Care Equipment & Services | Industry Group Name : Health Care Equipment & Supplies

Market Price : AUD 0.210.005 (2.439%)

(as on 2021-09-26 09:00:35)

Market Cap : AUD 37.21 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.205 0.21 0.21 0.21L 0.22 H 0.086L 0.305 H
Last Trade 0.21
Change% 2.4390
52 W H/L 0.305/0.086
EBITDA -3.501 M
NPAT After Abnormal Items -4.361 M
Equity 2.594 M
ROE% -168.10%
Total Liabilities 1.553 M
Total Revenue 166,765
Cash and Cash Equivalents 2.472 M

Stock Information

Share price 0.21
Market Cap 37.21 M
Price/Gross Cash Flow -6.07
Dividend Yield Excluding Special 0.00%
Ending Shares 150.039 M
52-Week Range 0.086-0.305
P/E ratio 0.000
Sector P/E --
EPS -3.51
EV/EBITDA --
Net Profit Margin (%) -8,500.28%
Gross Cash Flows Per Share -0.02
Net Gearing -85.69%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.01
Sales Per Share 0.00
Book Value Per Share 0.02

Announcements

Heading Date/Time
Positive Interim Results US Paid Pilot & 2nd Site Confirmed  13/09/2021 10:03AM
HeraCARE Shortlisted for Government tender in Spain  01/09/2021 9:42AM
Appendix 4D and Half Year Report  27/08/2021 5:47PM
Cleansing Prospectus  16/08/2021 6:39PM
HeraCARE paid pilot commences at Joondalup Health Campus  13/08/2021 8:26AM
Sheba Expands Pilot to include High-Risk Pregnancies  02/08/2021 9:35AM
Quarterly Activities & Cashflow Report  29/07/2021 9:14AM
Results of Meeting  23/07/2021 3:06PM
Change of Registered Office  19/07/2021 11:44AM
Update - Notice of Extraordinary General Meeting  19/07/2021 11:13AM
HeraCARE paid pilot commences with US-based Obstetrix Group  19/07/2021 9:07AM
Application for quotation of securities - HMD  14/07/2021 1:52PM
Application for quotation of securities - HMD  30/06/2021 5:56PM
Notice of Extraordinary General Meeting/Proxy Form  23/06/2021 5:58PM
Notification regarding unquoted securities - HMD  15/06/2021 6:48PM
Appendix 3G  15/06/2021 6:01PM
Results of Annual General Meeting  31/05/2021 3:25PM
Chairman's letter to shareholders  31/05/2021 11:08AM
Updated Investor Presentation and Webinar  17/05/2021 10:09AM
Pilot agreement signed with US leader Obstetrix Medical  13/05/2021 9:51AM
Trading Halt  11/05/2021 9:25AM
Appendix 2A  03/05/2021 5:38PM
Notice of Annual General Meeting/Proxy Form  29/04/2021 2:17PM
Quarterly Activities & Cashflow Report  28/04/2021 8:21AM
HeraCARE commercial agreement with Joondalup Health Campus  22/04/2021 9:23AM
Trading Halt  20/04/2021 9:35AM
Appendix 4G and Corporate Governance Statement  29/03/2021 8:09PM
Annual Report to shareholders  29/03/2021 8:07PM
JHC's Study Published One of Most Cited Scientific Journals  16/03/2021 8:25AM

Similar Companies

Related Articles

Load More

About Company

HeraMED is an Israeli company founded in 2011. Its flagship product is HeraBEAT, smartphone-based, efficient fetal heartbeat monitoring system for expectant mothers. As on 12th December, the company successfully completed its IPO of $6 million (NIS 15.8 million) at A$0.20 per share and subsequently listed on ASX.

Corporate Information

company address Suite 3, 23-25 Hunter Street, SYDNEY, NSW, AUSTRALIA, 2000

company phone+61 2 8379 2961

company websitehttp://www.hera-med.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/12/2020 -- 0.000 0.00%
30/12/2019 -- 0.000 0.00%
30/12/2018 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Interim) 2022-08-26 2022
Report (Annual) 2022-03-28 2022
Report (Prelim) 2022-02-25 2022

Financials

Breakdown 30/12/2020 30/12/2019 30/12/2018
Trading Revenue 51,306 207,520 109,335
Other Revenue 115,459 98,873 0
Total Revenue 166,765 306,394 109,335
Interest Income 17,451 55,097 0
Interest Expenses -13,405 -10,633 -1.263 M
Expenses -4.196 M -4.47 M -3.887 M
EBITDA -4.029 M -4.164 M -3.778 M
Depreciation and Amortization -335,853 -346,694 -295,161
Depreciation -6,608 -7,396 -9,589
Amortisation -329,244 -339,297 -285,572
EBIT -4.365 M -4.51 M -4.073 M
Pre Tax Profit -4.361 M -4.466 M -5.336 M
Tax Expense 0 0 0
Net Profit After Tax -4.361 M -4.466 M -5.336 M
Minority Interest 0 0 0
Preference Dividend 0 0 0
Net Abnormal Items 0 0 0
Reported Net Profit After Abnormal Items -4.361 M -4.466 M -5.336 M
Ending Shares 150.039 M 103.213 M 87.529 M
Weighted Average Shares 125.768 M 88.512 M 36.972 M
EPS After Abnormal Items (cents) -3.47 -5.05 -14.43
Breakdown 30/12/2020 30/12/2019 30/12/2018
Total Current Assets 2.865 M 3.366 M 6.116 M
Total Non Current Assets 1.282 M 1.778 M 1.712 M
Total Assets 4.147 M 5.144 M 7.828 M
Total Current Liabilities 669,837 769,790 708,968
Total Non Current Liabilities 883,064 965,949 969,941
Total Liabilities 1.553 M 1.736 M 1.679 M
Net Assets 2.594 M 3.408 M 6.149 M
Breakdown 30/12/2020 30/12/2019 30/12/2018
Net Operating Cash -3.608 M -3.892 M -2.502 M
Net Invested Cash -87,396 -295,782 -246,062
Net Financing Cash Flows 3.267 M 1.176 M 8.451 M
End Cash Position 2.472 M 2.92 M 5.715 M
Beginning Cash 2.656 M 5.758 M 64,613
Exchange Rate Adjustments 244,851 174,160 -51,581
Other Cash Adjustments 0 0 0
Ending Cash 2.472 M 2.92 M 5.715 M

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or ‘regulated financial advice’ under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ) at www.morningstar.com.au/s/fsg.pdf and www.morningstar.com.au/s/fapds.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyright and published under license from ASX Operations Pty Ltd ACN 004 523 782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK